Compare LTC Properties Inc (LTC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Mesoblast Limited — how do they compare? LTC Properties Inc trades at $42.46 (market cap $2.27B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: LTC Properties Inc is the larger of the two by market cap, and LTC Properties Inc pays a 5.42% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 88 Days and Mesoblast Limited for 15 Days on average.
| LTC | MESO | |
|---|---|---|
Market Cap | $2.27B | $1.75B |
Volume | 574,171 | 239,027 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $20.96 |
52-Week Low | $33.98 | $13.19 |
Typical Hold Time | 88 Days | 15 Days |
Enterprise Value | $3.01B | $1.83B |
Dividend Yield | 5.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $42.05, up 0.57% today, with mixed technical signals showing bearish overall momentum but bullish moving averages. The REIT demonstrates strong fundamentals with 38.93% net income margin and consistent dividend payments of $0.19 monthly. Recent strategic acquisitions totaling $360 million in SHOP properties signal aggressive growth plans while maintaining a manageable debt-to-asset ratio of 42.64%.
The outlook remains cautiously optimistic with a $49.67 consensus price target representing 18% upside potential. Key risks include rising interest rates impacting REIT valuations and execution challenges in the SHOP portfolio transition. Analyst sentiment is mixed with 32% buy ratings versus 55% hold, suggesting balanced risk-reward at current levels.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
